<DOC>
	<DOCNO>NCT00442286</DOCNO>
	<brief_summary>The purpose clinical trial demonstrate efficacy safety Rheos system subject hypertension resistant treatment least three anti-hypertension agent , one diuretic .</brief_summary>
	<brief_title>Rheos® Pivotal Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Be least 21 year age 80 year age . Have assess bilateral carotid bifurcation easily interrogate carotid duplex ultrasound level mandible . Office cuff systolic blood pressure great equal 160 mmHg diastolic blood pressure great equal 80 mmHg well 24hour ambulatory systolic blood pressure great equal 135 mmHg despite l one month maximally tolerate therapy least three antihypertensive medication , least one must diuretic . Must complete drug compliance questionnaire judge compliant medication . For subject prior bariatric surgery , must least 1 year postsurgery stable weight . If female , subject must surgically sterile , use medically accept method birth control agree continue use method duration trial . Women childbearing potential must negative serum pregnancy test preimplant blood evaluation . Must appropriate reasonable surgical candidate . Have sign CVRx approve informed consent form participation study Have know suspect baroreflex failure autonomic neuropathy . Have arm circumference great 46 cm and/or body mass index great 45 . Have significant cardiac bradyarrhythmias . Have chronic atrial fibrillation . Have significant orthostatic hypotension Had solid organ hematologic transplant . Had myocardial infarction , unstable angina , syncope , cerebral vascular accident within past 3 month . Have carotid atherosclerosis produce 50 % great reduction linear diameter determine ultrasound angiographic evaluation determine within 6 month enrollment trial . Have ulcerative plaque carotid artery determine ultrasound angiographic evaluation . Have prior surgery , radiation , endovascular stent placement either carotid sinus region . Have severe chronic kidney disease define : Currently undergo dialysis dialysis plan within 3 month implant date eGFR ≤30 ml/min/1.73m² Have hypertension secondary identifiable treatable cause sleep apnea . Have clinically significant cardiac structural valvular disease . Have clinically significant reactive airway disease , chronic obstructive pulmonary disease , and/or primary pulmonary hypertension . Have uncontrolled comorbid medical condition would adversely affect participation trial . Have clinically significant psychological illness would prohibit subject 's ability meet protocol requirement Are currently take imidazolone receptor agonist Are unable unwilling fulfill protocol medication compliance followup requirement . Have active infection within last month . Have comorbid condition reduces life expectancy le one year . Are enrol another concurrent clinical trial , without prior approval CVRx .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>High Blood Pressure</keyword>
	<keyword>Blood Pressure</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Resistant Hypertension</keyword>
	<keyword>Stage 2 Hypertension</keyword>
	<keyword>Hypertension resistant treatment</keyword>
</DOC>